Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 511-517

  Guo, Zhenying ^a   He, Yuanzheng ^b   Wang, Shuangshuang ^a   Zhang, Aixia ^a   Zhao, Ping ^b   Gao, Chongfeng ^b   Cao, Brian ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b VAN ANDEL INSTITUTE   (United States)

Author keywords

Breast cancer; Hepatoma derived growth factor; Prostate cancer; Small interfering RNA

Indexed keywords

CELL PROTEIN; HEPATOMA DERIVED GROWTH FACTOR; PROTEIN PIK3R1; PROTEIN SERPINE1; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL STIMULATION; CELL STRAIN DU145; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79958234730     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1295     Document Type: Article

References (30)

1. Nakamura H, Kambe H, Egawa T, et al: Partial purification and characterization of hepatoma-derived growth factor. Clin Chim Acta 183: 273-284, 1989.
2. Nakamura H, Izumoto Y, Kambe H, et al: Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269: 25143-25149, 1994.
3. Okuda Y, Nakamura H, Yoshida K, et al: Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 94: 1034-1041, 2003.
4. Izumoto Y, Kuroda T, Harada H, Kishimoto T and Nakamura H: Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino acid terminus. Biochem Biophys Res Commun 238: 26-32, 1997.
5. Kishima Y, Yamamoto H, Izumoto Y, et al: Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 277: 10315-10322, 2002.
6. Everett AD, Stoops TD and McNamara CA: Nuclear targeting is required for hepatoma-derived growth factor stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 276: 37564-37568, 2001.
7. Oliver JA and Al-Awqati Q: An endothelial growth factor involved in rat renal development. J Clin Invest 102: 1208-1219, 1998.
8. Everett AD, Lobe DR, Matsumura ME, Nakamura H and McNamara CA: Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105: 567-575, 2000.
9. Enomoto H, Yoshida K, Kishima Y, et al: Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 36: 1519-1527, 2002.
10. Kishima Y, Yoshida K, Enomoto H, et al: Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 49: 1639-1644, 2002.
11. Zhou SJ, Xu SF, Zhang HQ and Liu ZD: Expression of HDGF and its implication in stage I non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 29: 927-930, 2007.
12. Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K and Kawahara K: Hepatoma-derived growth factor as a prognostic marker in completely resected non-small cell lung cancer. Oncol Rep 13: 1075-1080, 2005.
13. Ren H, Tang X, Lee JJ, et al: Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small cell lung cancer. J Clin Oncol 22: 3230-3237, 2004.
14. Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L: Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66: 18-23, 2006.
15. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang BL and Hoshida Y: Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12: 6043-6048, 2006.
16. Zhang A, Long W, Guo Z, et al: Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients. J Immunol Methods 15: 61-67, 2010.
17. Gridley DS, Slater J, Luo-Owen X, et al: Spaceflight effects on T lymphocyte distribution, function and gene expression. J Appl Physiol 106: 194-202, 2009.
18. Uchino M, Kojima H, Wada K, et al: Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer 10: 414, 2010.
19. Ashida S, Nakagawa H, Katagiri T, et al: Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64: 5963-5972, 2004.
20. Everett AD, Narron JV, Stoops T, Nakamura H and Tucker A: Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286: L1194-L1201, 2004.
21. Mori M, Morishita H, Nakamura H, et al: Hepatoma-derived growth factor is involved in lung remodeling by stimulating epithelial growth. Am J Respir Cell Mol Biol 30: 459-469, 2004.
22. Yamamoto S, Tomita Y, Hoshida Y, et al: Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12: 117-122, 2006.
23. Yoshida K, Tomita Y, Okuda Y, et al: Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13: 159-167, 2006.
24. Zhou Y, Zhou N, Fang W and Huo J: Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol 5: 58, 2010.
25. Hu TH, Lin JW Chen HH, Liu LF, Chuah SK and Tai MH: The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum 52: 319-326, 2009.
26. Liu YF, Zhao R, Guo S, Wang XQ, Lian PL, Chen YG and Xu KS: Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol 18: 872-879, 2011.
27. Mao J, Xu Z, Fang Y, et al: Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci 99: 2120-2127, 2008.
28. Tsang TY, Tang WY, Tsang WP, Co NN, Kong SK and Kwok TT: Down-regulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis 13: 1135-1147, 2008.
29. Liao F, Liu M, Lv L and Dong W: Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordi-hydroguaiaretic acid in colorectal cancer cells. Eur J Pharmacol 645: 55-62, 2010.
30. Wang CH, Davamani F, Sue SC, et al: Cell surface heparan sulfates mediated internalization of PWWP/HATH domain of HDGF via macropinocytosis to fine-tune cell signaling process involved in and its effect on fibroblast cell migration. Biochem J 433: 127-138, 2010.